Navigation Links
AEterna Zentaris Announces Positive Preliminary Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Ovarian Cancer
Date:11/2/2009

ent recruitment was planned in 2 stages with 21 and 20 patients, respectively, and the primary efficacy endpoint at the end of stage 2 was defined as 5 or more patients with partial or complete tumor responses according to Response Evaluation Criteria in Solid Tumors (RECIST) and/or Gynaecologic Cancer Intergroup (GCIG) guidelines. Secondary endpoints include time to progression, survival, toxicity, as well as adverse effects.

About Ovarian and Endometrial Cancer

Ovarian cancer is one of the most common gynaecologic malignancies and the fifth most frequent cause of cancer death in women, with most of the cases occurring in women between 50 and 75 years of age. Overall, ovarian cancer accounts for 4% of all cancer diagnoses in women and 5% of all cancer deaths. Approximately 26,000 new cases and 17,000 deaths from this disease are estimated in the European community every year (Source: Gynaecologic Oncology, Volume 92, Issue 3, March 2004, Pages 819-826).

Cancer of the endometrium is the most common gynaecologic malignancy and accounts for 6% of all cancers in women. The majority of the cases occur in postmenopausal women, with the largest number of women developing their cancers during their sixth decade. Approximately 38,000 new cases and 9,000 deaths from this disease are estimated annually in Europe (Source: Annals of Oncology 15:1149-1150, 2004).

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology, with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. AEterna Zentaris to Announce Third Quarter 2007 Financial and Operating Results on November 7, 2007
2. AEterna Zentaris Announces First Patient Dosing for Safety Trial of Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
3. AEterna Zentaris Reports First Quarter 2009 Financial and Operating Results
4. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
5. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
6. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
7. HEI, Inc. Announces Sale of RFID Division Assets
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
9. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
10. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
11. Brooke Franchise Corporation Announces Selected July Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Catalent Pharma Solutions, the leading global ... for drugs, biologics and consumer health products, has ... and technology offer based on the company’s expertise ... 450,000 sq. ft. Kansas City, MO facility. , ... formulation, development, analytical expertise, scale up and manufacturing ...
(Date:9/17/2014)... JOLLA, CASeptember 17, 2014Scientists at The Scripps Research ... on vancomycin that is powerfully effective against vancomycin-resistant ... The new vancomycin analog appears to have not ... against which bacteria probably cannot evolve resistance quickly. ... once introduced will still be in clinical use ...
(Date:9/17/2014)... 17, 2014 Boston Children’s Museum ... a monthly concert series, introducing young Museum visitors ... Top, America’s premier national platform celebrating the stories, ... of the young musicians featured will also be ... Children’s Museum is fortunate to partner with the ...
(Date:9/17/2014)... A petition to ban the use of ... other gynecological surgeries has gathered nearly 85,000 signatures, Bernstein ... at least 84,908 supporters had signed the petition as ... report from ABC News, the Change.org petition was launched ... his wife, Dr. Amy Reed, was diagnosed with Stage ...
(Date:9/17/2014)... WEDNESDAY, Sept. 17, 2014 (HealthDay News) -- Present-day ... groups of ancient humans, according to a new ... descended from indigenous hunter-gatherers and early European farmers. ... samples revealed they are also the descendants of ... genetic material from this third ancestral group, researchers ...
Breaking Medicine News(10 mins):Health News:New OptiPact™ Technology Introduced by Catalent 2Health News:Scripps Research Institute chemists modify antibiotic to vanquish resistant bacteria 2Health News:Scripps Research Institute chemists modify antibiotic to vanquish resistant bacteria 3Health News:Boston Children's Museum Partners with From the Top to Offer Monthly Concert Series 2Health News:Boston Children's Museum Partners with From the Top to Offer Monthly Concert Series 3Health News:Power Morcellator Petition Nears 85,000 Signatures, Bernstein Liebhard LLP Reports 2Health News:Power Morcellator Petition Nears 85,000 Signatures, Bernstein Liebhard LLP Reports 3Health News:Power Morcellator Petition Nears 85,000 Signatures, Bernstein Liebhard LLP Reports 4Health News:Europeans Are Descendants of at Least 3 Ancient Human Groups: Study 2Health News:Europeans Are Descendants of at Least 3 Ancient Human Groups: Study 3
... Pancreatic cancer develops and spreads much more slowly than ... Hopkins investigators. The finding indicates that there is a ... disease. "For the first time, we have a ... when it would be best to intervene," according to ...
... tumors are one of the most lethal cancers, with fewer ... But a new study that peers deeply into the genetics ... opportunity for early diagnosis. In contrast to earlier predictions, many ... years to become lethal after the first genetic perturbations appear. ...
... PHILADELPHIA Demetrius H. Bagley, M.D., the Nathan Lewis Hatfield ... Medical College (JMC) of Thomas Jefferson University was recently honored ... Award in Endourology at the World Congress of Endourology. ... is fitting that Dr. Bagley was chosen to receive the ...
... News) --Mental health issues confronted by U.S. veterans returning ... by gender, new research suggests. Female veterans ... than are their male counterparts, according to a study ... the Veterans Administration from 2002 to 2008. They are ...
... efficient as humans mature. Now, for the first time ... Polytechnique Fdrale de Lausanne (EPFL) and the University of ... verified these gains with a powerful new computer program. ... the soon-to-be-released software allows for individualized maps of vital ...
... and University of North Carolina (UNC) researchers report in ... that narcotics and diagnostic testing are overused in ... overlook more effective treatments for neck pain, such as ... evidence to support the effectiveness of therapeutic exercise in ...
Cached Medicine News:Health News:Surprise finding: Pancreatic cancers progress to lethal stage slowly 2Health News:Surprise finding: Pancreatic cancers progress to lethal stage slowly 3Health News:Revising the timeline for deadly pancreatic cancer 2Health News:Revising the timeline for deadly pancreatic cancer 3Health News:Jefferson urologist awarded Lifetime Achievement Award from Endourological Society 2Health News:Mental Health Issues Differ for U.S. Male, Female Vets 2Health News:The brain's journey from early Internet to modern-day fiber optics -- all in 1 lifetime 2Health News:Narcotics and diagnostics overused in treatment of chronic neck pain 2
(Date:9/17/2014)... NEW YORK , Sept. 17, 2014 ... on behalf of purchasers of the securities of PDL ... PDLI -News).  Such investors are advised to ... coordinator Eitan Kimelman at info@bgandg.com ... the Company and certain of its executives violated federal ...
(Date:9/17/2014)... EDEN PRAIRIE, Minn. , Sept. 17, 2014 /PRNewswire/ ... pioneer and global market leader of advanced imaging modalities ... Intravascular Ultrasound System in two live cases at the ... The cases were presented from Medstar Washington ... New York-Presbyterian Hospital/Columbia University Medical Center ( New ...
(Date:9/17/2014)... DALLAS , Sept. 17, 2014   OTEMR, ... 2014 Edition Complete EHR certification, which designates that the ... the Stage 1 and Stage 2 Meaningful Use measures ... and Reinvestment Act (ARRA).  ONETOUCH EMR 2.0 was certified ... an Office of the National Coordinator-Authorized Certification Body (ONC-ACB) ...
Breaking Medicine Technology:Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Investigates claims on behalf of Investors of PDL BioPharma, Inc. --PDLI 2ACIST Launches HDi High-Definition IVUS 2ACIST Launches HDi High-Definition IVUS 3OTEMR, Inc.'s ONETOUCH EMR Achieves ONC HIT 2014 Edition COMPLETE EHR Certification from ICSA Labs 2OTEMR, Inc.'s ONETOUCH EMR Achieves ONC HIT 2014 Edition COMPLETE EHR Certification from ICSA Labs 3
... speed and efficiency in the healthcare process remains ... essential variables to ensure healthy, accurate outcomes. Rising ... Align Networks, a physical medicine provider network, have ... pace of healthcare. (Logo:   http://photos.prnewswire.com/prnh/20080206/AQW030LOGO-b ...
... Cynosure, Inc. (Nasdaq: CYNO ), ... array of light-based aesthetic treatment systems, today announced ... financial results before the market opens on Tuesday, ... investors and analysts that day at 9:00 a.m. ...
Cached Medicine Technology:Realizing Healthcare Savings Using Real-Time Technology 2Realizing Healthcare Savings Using Real-Time Technology 3Cynosure to Host Third-Quarter 2010 Financial Results Conference Call on October 26 2
This 100 µL is the equivalent to the "Universal Blue" tips and fits virtually every manufacturer's 1000 µL Pipettor....
Conducting disposable tips provide cross-contaminationfree pipetting for sensitive applications such as PCR setup....
Volume range 0.2-10 l. Designed for pipetting micro-sized drops. Ideal for use with micro volume Finnpipettes....
Conducting disposable tips....
Medicine Products: